MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH — Pharma major Lupin and Mylan announced that the two companies will partner to commercialize a biosimilar to Enbrel (etanercept). Through the partnership agreement, Mylan will commercialize Lupin’s proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia. Enbrel is a TNF-inhibitor indicated to
BALTIMORE — Lupin announced the appointment of Nicholas (Nick) Hart as president – specialty for its U.S. business. Hart will lead the specialty strategic business unit in the United States and will be responsible for Lupin’s specialty brand business growth strategy, P&L and organization. Hart brings over 25 years of specialty business, strategic and commercial operations experience to
MUMBAI, India — Lupin Ltd. plans to buy Gavis Pharmaceuticals LLC and Novel Laboratories Inc. in an $880 million deal. Lupin said Thursday that the acquisition will boost its scale in the U.S. generic drug market and broadens its pipeline in dermatology, controlled-substance products, and other high-value and niche generics. In addition, Gavis brings a
